Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →ROR1 is highly expressed on the surface of triple-negative breast cancer cells but minimally expressed on normal adult tissues, making it a promising candidate…
Boehringer Ingelheim is paying up to EUR 1.18 billion ($1.4 billion) to acquire Swiss biotech NBE-Therapeutics, snagging an immune-stimulatory ADC platform and…
In 2021, the American Cancer Society estimates 281,550 new cases of invasive breast cancer and 43,600 breast cancer deaths in U.S. women. Triple-negative…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Boehringer Ingelheim signed a binding agreement to acquire Swiss biotech NBE-Therapeutics for EUR 1.18B (~$1.4B); the deal closed March 4, 2021. It brought NBE's immune-stimulatory ADC (iADC) platform plus lead asset NBE-002 (zinitevatug), an anti-ROR1 ADC then in Phase 1 for TNBC and solid tumors, complementing Boehringer's antigen-discovery and T-cell-engager capabilities and entering the increasingly competitive ROR1 ADC race alongside Merck/VelosBio. Post-close, the program did not pan out: the NBE-002 Phase 1/2 trial (NCT04441099) was terminated for "End of Program" with a primary completion date of August 14, 2023, having enrolled only 12 of a planned ~100 patients. The acquisition's central clinical asset was thus discontinued, leaving the iADC platform as the residual value of the transaction.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim GmbH / NBE-Therapeutics AG (this deal) | 2020 | $1.4B | — |
| Boehringer Ingelheim GmbH / Amgen Inc. (Fremont manufacturing facility) | 2011 | — | 77 |
| Boehringer Ingelheim GmbH / NBE Therapeutics | 2020 | $1.5B | 28 |
| Boehringer Ingelheim GmbH / AMAL Therapeutics SA | 2019 | $366M | — |
| Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. | 2019 | $1.2B | — |
| Boehringer Ingelheim GmbH / Yuhan Corporation | 2019 | $870M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
← Browse all deals · How we score deals
More: 2020 deals · Boehringer Ingelheim GmbH deals · Oncology deals